Compare Goldman Sachs Physical Gold ETF (AAAU) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs Adaptive Biotechnologies Corp — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.46, while Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B). The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | ADPT | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $25.45 |
52-Week Low | $32.74 | $12.30 |
Market Cap | — | $4.04B |
Enterprise Value | — | $4.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU trades at $43.42, up 0.35% today, with a bullish technical signal from moving averages but bearish oscillators. Key support is at $42 and resistance at $44. Recent news highlights gold's strength amid cooling U.S. inflation and geopolitical tensions, with spot gold reaching $4,438/oz. Financial ratios are unavailable, limiting fundamental assessment.
The outlook for AAAU is supported by positive gold market dynamics, including central bank demand and inflation trends. Risks include potential Fed policy shifts and market volatility. Analyst sentiment is mixed, with technical indicators suggesting caution despite bullish momentum.
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
